Ken Griffin’s Cardiff Oncology CRDF Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $203K | Buy |
125,566
+7,378
| +6% | +$15.2K | ﹤0.01% | 11391 |
|
|
2025
Q4 | $332K | Buy |
118,188
+95,823
| +428% | +$222K | ﹤0.01% | 9917 |
|
|
2025
Q3 | $46.1K | Buy |
+22,365
| New | +$61.8K | ﹤0.01% | 12245 |
|
|
2025
Q2 | – | Sell |
-757,840
| Closed | -$2.31M | – | 12869 |
|
|
2025
Q1 | $2.38M | Buy |
757,840
+688,487
| +993% | +$2.72M | ﹤0.01% | 5195 |
|
|
2024
Q4 | $301K | Buy |
69,353
+18,807
| +37% | +$58.8K | ﹤0.01% | 9646 |
|
|
2024
Q3 | $135K | Sell |
50,546
-5,250
| -9% | -$12.4K | ﹤0.01% | 10695 |
|
|
2024
Q2 | $124K | Buy |
+55,796
| New | +$210K | ﹤0.01% | 10617 |
|
|
2024
Q1 | – | Sell |
-27,760
| Closed | -$73.8K | – | 14658 |
|
|
2023
Q4 | $41.1K | Buy |
+27,760
| New | +$33.6K | ﹤0.01% | 11989 |
|
|
2023
Q3 | – | Sell |
-86,123
| Closed | -$145K | – | 14384 |
|
|
2023
Q2 | $127K | Buy |
86,123
+79,116
| +1,129% | +$128K | ﹤0.01% | 10571 |
|
|
2023
Q1 | $11.6K | Buy |
7,007
+1,291
| +23% | +$2.22K | ﹤0.01% | 13466 |
|
|
2022
Q4 | $8K | Sell |
5,716
-194,544
| -97% | -$279K | ﹤0.01% | 13776 |
|
|
2022
Q3 | $308K | Buy |
200,260
+70,763
| +55% | +$170K | ﹤0.01% | 9510 |
|
|
2022
Q2 | $285K | Sell |
129,497
-472,980
| -79% | -$792K | ﹤0.01% | 9919 |
|
|
2022
Q1 | $1.49M | Buy |
602,477
+438,354
| +267% | +$1.55M | ﹤0.01% | 6734 |
|
|
2021
Q4 | $987K | Sell |
164,123
-712,525
| -81% | -$4.25M | ﹤0.01% | 7991 |
|
|
2021
Q3 | $5.84M | Sell |
876,648
-306,902
| -26% | -$1.93M | ﹤0.01% | 4014 |
|
|
2021
Q2 | $7.87M | Sell |
1,183,550
-115,516
| -9% | -$980K | ﹤0.01% | 3529 |
|
|
2021
Q1 | $12M | Buy |
1,299,066
+432,101
| +50% | +$5.25M | ﹤0.01% | 2705 |
|
|
2020
Q4 | $15.6M | Buy |
866,965
+710,854
| +455% | +$12.5M | ﹤0.01% | 2088 |
|
|
2020
Q3 | $2.21M | Buy |
+156,111
| New | +$1.03M | ﹤0.01% | 4532 |
|
|
2018
Q4 | – | Sell |
-3,043
| Closed | -$15K | – | 9185 |
|
|
2018
Q3 | $15K | Sell |
3,043
-876
| -22% | -$4.15K | ﹤0.01% | 9065 |
|
|
2018
Q2 | $18K | Buy |
+3,919
| New | +$65.5K | ﹤0.01% | 8668 |
|
|
2017
Q4 | – | Sell |
-148
| Closed | -$8K | – | 8011 |
|
|
2017
Q3 | $8K | Buy |
+148
| New | +$9.23K | ﹤0.01% | 7445 |
|
|
2017
Q2 | – | Sell |
-364
| Closed | -$30K | – | 7554 |
|
|
2017
Q1 | $30K | Buy |
+364
| New | +$49.4K | ﹤0.01% | 7168 |
|
|
2016
Q2 | – | Sell |
-352
| Closed | -$118K | – | 6881 |
|
|
2016
Q1 | $118K | Buy |
352
+143
| +68% | +$48.7K | ﹤0.01% | 5956 |
|
|
2015
Q4 | $81K | Buy |
+209
| New | +$81.8K | ﹤0.01% | 6894 |
|
|
2014
Q2 | – | Sell |
-173
| Closed | -$72K | – | 7990 |
|
|
2014
Q1 | $72K | Buy |
+173
| New | +$74.9K | ﹤0.01% | 6473 |
|
Other funds holding CRDF
VCM
LCM
P
ACA
FLPIM
Ken Griffin's CRDF Position: Q1 2026 in Review
Ken Griffin increased its Cardiff Oncology (CRDF) stake by 6.2% in Q1 2026, buying an estimated $15.2K and bringing the position to 125,566 shares worth $203K. The position accounts for ﹤0.01% of the portfolio, ranked #11391.
Ken Griffin first reported a position in CRDF in Q1 2014 and has held it in 27 quarters since. The position peaked at $15.6M in Q4 2020. 117 funds tracked by Wall St. Rank hold CRDF as of Q1 2026.
- Ken Griffin held 125,566 shares of Cardiff Oncology worth $203K as of Q1 2026.
- Ken Griffin bought 7,378 Cardiff Oncology shares in Q1 2026, an estimated $15.2K.
- Cardiff Oncology made up ﹤0.01% of Ken Griffin's portfolio in Q1 2026, its #11391 holding.
- Ken Griffin first reported a position in Cardiff Oncology in Q1 2014 and has held it in 27 quarters since.
- Ken Griffin's Cardiff Oncology position peaked at $15.6M in Q4 2020.
- 117 funds tracked by Wall St. Rank held Cardiff Oncology as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.